ClinicalTrials.gg
TerminatedNCT03152084DAPASALTUpdated May 28, 2021Results posted

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

A Phase 4 interventional study of Dapagliflozin in Diabetes Mellitus, Type 2 and Kidney Function Tests, sponsored by AstraZeneca. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-28.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was terminated
Poor recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
154th of 180
24 · median 82
Started
2017
with 12 others
Phase 4
77 of 180
7 open now
Registered
96th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 154th largest by enrollment, is one of 13 that started in 2017, is one of 77 in phase 4, and was the 96th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Kidney Function Tests
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures
  • Female and/or male aged between 18 years and ≤80 years
  • In the diabetic arms - a diagnosis of T2DM with ≥6.5% (≥48 mmol/mol) and \<10% (\<86 mmol/mol); and (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 or between >90 and ≤130 mL/min/1.73m2 for patients aged 59 years or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69 years, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 years or older at the Screening Visit (Visit 1)
  • In the non-diabetic arm, HbA1c \<6.5% (\<48 mmol/mol) and an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit (Visit 1)
  • Patient specific optimal antihypertensive dose of an angiotensin receptor blocker at least 6 weeks before study treatment
  • In the diabetic arm (Group 2) an appropriate stable dose of metformin, or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks before study treatment
  • Stable urinary sodium excretion on 2 successive 24-hr urinary sodium excretion measurements.
  • In the diabetic arm with impaired renal function (Group 1), a stable insulin dosing (intermediate, long-acting, premixed insulin, basal bolus insulin) for the last 12 weeks prior to Visit 4 (Day 1), as judged by the Investigator. Metformin or sulphonylurea, or metformin+sulphonylurea together with insulin would be accepted, but is not mandatory. If used, stable dose of metformin or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks prior to Visit 4 (Day 1) is required.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 Diabetes Mellitus
  • Any of the following cardiovascular/vascular diseases within 3 months prior to signing the consent; myocardial infarction, cardiac surgery or revascularization, unstable angina, unstable heart failure, heart failure Class IV, or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia
  • Symptoms/complaints suggestive of established neurogenic bladder and/or incomplete bladder emptying
  • History of bladder cancer, diagnosis of polycystic kidney disease, history or current lupus nephritis or unstable or rapidly progressing renal disease
  • UACR >1000 mg/g at screening
  • Current/chronic use of the following medications: any anti-diabetic medication with the exception of metformin, sulphonylurea, angiotensin converting enzyme inhibitors, insulin (insulin only allowed in Group 1), oral , non-steroidal anti-inflammatory drugs, immune suppressants, chemotherapeutics, antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors
  • Receiving or other immunotherapy for primary or secondary renal disease within 6 months prior to screening
  • Current treatment or treatment within the last 2 weeks prior to screening with diuretics including loop diuretics, thiazides, and mineralocorticoid antagonists
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Arm 1

    T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.

    Drug: Dapagliflozin

  • Experimental
    Arm 2

    T2DM subjects with an eGFR (CKD-EPI) between \>90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between \>85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between \>75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.

    Drug: Dapagliflozin

  • Experimental
    Arm 3

    Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.

    Drug: Dapagliflozin

Interventions

  • The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.

06

What researchers measure

Primary outcomes

  1. Change in 24-hour Sodium Excretion From Baseline to Start of Treatment

    Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.

    Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)

Secondary outcomes

  1. Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up

    Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).

    Time frame: From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)

  2. Change in 24-hour Glucose Excretion From Baseline to Start of Treatment

    Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).

    Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)

  3. Change in 24-hour Glucose Excretion From Baseline to End of Treatment

    Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)

    Time frame: From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)

  4. Change in 24-hour Glucose Excretion From End of Treatment to Follow-up

    Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).

    Time frame: From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)

  5. Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment

    Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)

    Time frame: From baseline (Day -1) to start of treatment (Day 4)

  6. Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment

    Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).

    Time frame: From baseline (Day -1) to end of treatment (Day 13)

  7. Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up

    Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).

    Time frame: From end of treatment (Day 13) to end of follow-up (Day 18)

  8. Change in Plasma Volume From Baseline to Start of Treatment

    Change in plasma volume from baseline to start of treatment (Day 4).

    Time frame: From baseline (Day 1) to start of treatment (Day 4)

  9. Change in Plasma Volume From Baseline to End of Treatment

    Change in plasma volume from baseline to end of treatment (Day 14).

    Time frame: From baseline (Day 1) to end of treatment (Day 14)

  10. Change in Plasma Volume From End of Treatment to End of Follow-up

    Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).

    Time frame: From end of treatment (Day 14) to end of follow-up (Day 18)

  11. Change in Extracellular Volume From Baseline to Start of Treatment

    Change in extracellular volume from baseline to start of treatment (Day 4).

    Time frame: From baseline (Day 1) to start of treatment (Day 4)

  12. Change in Extracellular Volume From Baseline to End of Treatment

    Change in extracellular volume from baseline to end of treatment (Day 14).

    Time frame: From baseline (Day 1) to end of treatment (Day 14)

  13. Change in Extracellular Volume From End of Treatment to End of Follow-up

    Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).

    Time frame: From end of treatment (Day 14) to end of follow-up (Day 18)

  14. Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)

    Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).

    Time frame: From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)

  15. Pharmacokinetics of Dapagliflozin on Day 4 and Day 14

    Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)

    Time frame: At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)

  16. Number of Patients With AEs and SAEs

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.

    Time frame: From Day 1 until Day 18 (Follow-up)

07

Results

Posted May 28, 2021
Limitations and caveats
The study was prematurely closed due to unsatisfactory recruitment rate. Of 5 patients enrolled in the Group 1, none were enrolled into the Run-in set due to failure to meet inclusion/exclusion criteria, screen failure, withdrawal or other reason and hence it was decided that no more Group 1 patients would be enrolled in the study. In Group 2 and 3, 17 and 7 patients received the investigational product and completed the study, respectively.

Participant flow

The study was conducted between 12-Jul-2017 and 20-Mar-2020. Patients who met all the inclusion and none of the exclusion criteria were enrolled in the study.

Participant flow — Overall Study
MilestoneGroup 2Group 3
Started177
Completed177
Not completed00

Outcome measures

PrimaryChange in 24-hour Sodium Excretion From Baseline to Start of Treatment

Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.

Time frame:
From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)
Reported as:
Median · mmol/24 hour
Change in 24-hour Sodium Excretion From Baseline to Start of Treatment
mmol/24 hourGroup 2Group 3
Change in 24-hour Sodium Excretion From Baseline to Start of Treatment-5.33 (-53.667 to 44.000)-27.67 (-69.334 to 13.334)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.4462 (Start of treatment vs baseline) · Least square mean: -5.21 · 95% CI -19.542 to 9.120
SecondaryChange in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up

Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).

Time frame:
From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)
Reported as:
Median · mmol/24 hour
Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up
mmol/24 hourGroup 2Group 3
End of treatment vs baseline2.67 (-64.000 to 143.167)-23.83 (-107.000 to 0.667)
Follow-up vs end of treatment1.33 (-135.334 to 25.000)6.17 (-70.333 to 20.333)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.7842 (End of treatment vs baseline) · Least square mean: 3.69 · 95% CI -24.817 to 32.195
  • Group 2 · Regression, Linear · p = 0.0581 (Follow-up vs End of treatment) · Least square mean: -16.72 · 95% CI -34.109 to 0.664
SecondaryChange in 24-hour Glucose Excretion From Baseline to Start of Treatment

Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).

Time frame:
From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)
Reported as:
Median · mmol/24 hour
Change in 24-hour Glucose Excretion From Baseline to Start of Treatment
mmol/24 hourGroup 2Group 3
Change in 24-hour Glucose Excretion From Baseline to Start of Treatment302.61 (191.472 to 635.726)43.93 (12.050 to 132.333)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = <0.0001 (Start of treatment vs baseline) · Least square mean: 344.85 · 95% CI 272.785 to 416.905
SecondaryChange in 24-hour Glucose Excretion From Baseline to End of Treatment

Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)

Time frame:
From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)
Reported as:
Median · mmol/24 hour
Change in 24-hour Glucose Excretion From Baseline to End of Treatment
mmol/24 hourGroup 2Group 3
Change in 24-hour Glucose Excretion From Baseline to End of Treatment283.40 (155.876 to 762.801)29.88 (15.450 to 113.300)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = <0.0001 (End of treatment vs baseline) · Least square mean: 311.30 · 95% CI 224.528 to 398.064
SecondaryChange in 24-hour Glucose Excretion From End of Treatment to Follow-up

Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).

Time frame:
From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)
Reported as:
Median · mmol/24 hour
Change in 24-hour Glucose Excretion From End of Treatment to Follow-up
mmol/24 hourGroup 2Group 3
Change in 24-hour Glucose Excretion From End of Treatment to Follow-up-168.43 (-376.561 to -107.596)-37.02 (-74.733 to -10.584)
Statistical analysis
  • Group 2 · Regression, Linear · p = <0.0001 (Follow-up vs end of treatment) · Least square mean: -203.07 · 95% CI -235.983 to -170.162
SecondaryChange in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment

Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)

Time frame:
From baseline (Day -1) to start of treatment (Day 4)
Reported as:
Median · mmHg
Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment
mmHgGroup 2Group 3
Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment-5.4810 (-13.6610 to 5.6100)-8.9730 (-24.6570 to 2.7210)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.0047 (Start of treatment vs baseline) · Least square mean: -5.2658 · 95% CI -8.5459 to -1.9856
SecondaryChange in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment

Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).

Time frame:
From baseline (Day -1) to end of treatment (Day 13)
Reported as:
Median · mmHg
Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment
mmHgGroup 2Group 3
Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment-5.9385 (-16.0060 to 0.9160)-10.3290 (-23.4160 to 16.2160)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.0003 (End of treatment vs baseline) · Least square mean: -7.0987 · 95% CI -10.0379 to -4.1595
SecondaryChange in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up

Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).

Time frame:
From end of treatment (Day 13) to end of follow-up (Day 18)
Reported as:
Median · mmHg
Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up
mmHgGroup 2Group 3
Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up2.5140 (-10.3420 to 8.4590)-2.6590 (-16.3110 to 7.4680)
Statistical analysis
  • Group 2 · Regression, Linear · p = 0.5592 (Follow-up vs end of treatment) · Least square mean: 0.7287 · 95% CI -1.9894 to 3.4468
SecondaryChange in Plasma Volume From Baseline to Start of Treatment

Change in plasma volume from baseline to start of treatment (Day 4).

Time frame:
From baseline (Day 1) to start of treatment (Day 4)
Reported as:
Median · Litres
Change in Plasma Volume From Baseline to Start of Treatment
LitresGroup 2Group 3
Change in Plasma Volume From Baseline to Start of Treatment-0.1440 (-1.7819 to 2.6385)-0.1139 (-2.0340 to 0.0232)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.9288 (Start of treatment vs baseline) · Least square mean: 0.0315 · 95% CI -0.7274 to 0.7904
SecondaryChange in Plasma Volume From Baseline to End of Treatment

Change in plasma volume from baseline to end of treatment (Day 14).

Time frame:
From baseline (Day 1) to end of treatment (Day 14)
Reported as:
Median · Litres
Change in Plasma Volume From Baseline to End of Treatment
LitresGroup 2Group 3
Change in Plasma Volume From Baseline to End of Treatment-0.2122 (-2.8346 to 1.1073)2.0557 (2.0557 to 2.0557)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.1659 (End of treatment vs baseline) · Least square mean: -0.4318 · 95% CI -1.0761 to 0.2125
SecondaryChange in Plasma Volume From End of Treatment to End of Follow-up

Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).

Time frame:
From end of treatment (Day 14) to end of follow-up (Day 18)
Reported as:
Median · Litres
Change in Plasma Volume From End of Treatment to End of Follow-up
LitresGroup 2Group 3
Change in Plasma Volume From End of Treatment to End of Follow-up0.6464 (-1.5016 to 1.6410)—
Statistical analysis
  • Group 2 · Regression, Linear · p = 0.0190 (Follow-up vs end of treatment) · Least square mean: 0.4755 · 95% CI 0.0963 to 0.8548
SecondaryChange in Extracellular Volume From Baseline to Start of Treatment

Change in extracellular volume from baseline to start of treatment (Day 4).

Time frame:
From baseline (Day 1) to start of treatment (Day 4)
Reported as:
Median · Litres
Change in Extracellular Volume From Baseline to Start of Treatment
LitresGroup 2Group 3
Change in Extracellular Volume From Baseline to Start of Treatment-0.5783 (-2.7027 to 0.7959)-0.4553 (-1.3758 to 0.2282)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.0157 (Start of treatment vs baseline) · Least square mean: -0.6713 · 95% CI -1.1914 to -0.1511
SecondaryChange in Extracellular Volume From Baseline to End of Treatment

Change in extracellular volume from baseline to end of treatment (Day 14).

Time frame:
From baseline (Day 1) to end of treatment (Day 14)
Reported as:
Median · Litres
Change in Extracellular Volume From Baseline to End of Treatment
LitresGroup 2Group 3
Change in Extracellular Volume From Baseline to End of Treatment0.1248 (-1.4948 to 0.9852)-0.1427 (-0.6101 to 1.0055)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.8700 (End of treatment vs baseline) · Least square mean: -0.0324 · 95% CI -0.4631 to 0.3984
SecondaryChange in Extracellular Volume From End of Treatment to End of Follow-up

Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).

Time frame:
From end of treatment (Day 14) to end of follow-up (Day 18)
Reported as:
Median · Litres
Change in Extracellular Volume From End of Treatment to End of Follow-up
LitresGroup 2Group 3
Change in Extracellular Volume From End of Treatment to End of Follow-up0.1784 (-0.6507 to 0.9780)0.1394 (-0.3045 to 0.9014)
Statistical analysis
  • Group 2 · Regression, Linear · p = 0.2446 (Follow-up vs end of treatment) · Least square mean: 0.1718 · 95% CI -0.1358 to 0.4795
SecondaryChange in 24-hour Urine Albumin:Creatinine Ratio (UACR)

Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).

Time frame:
From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)
Reported as:
Median · mg/mmol
Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)
mg/mmolGroup 2Group 3
Start of treatment vs baseline-0.07 (-30.750 to 6.700)-5.83 (-35.300 to 0.300)
End of treatment vs baseline-0.04 (-17.250 to 0.737)-7.28 (-35.733 to 0.467)
Follow-up vs end of treatment0.07 (-0.243 to 51.667)-0.19 (-2.967 to 6.367)
Statistical analysis
  • Group 2 · Mixed Models Analysis · p = 0.0023 (Start of treatment vs baseline) · Least square mean: -2.10 · 95% CI -3.299 to -0.902
  • Group 2 · Mixed Models Analysis · p = <0.0001 (End of treatment vs baseline) · Least square mean: -1.59 · 95% CI -1.929 to -1.256
  • Group 2 · Regression, Linear · p = 0.0002 (Follow-up vs end of treatment) · Least square mean: 3.88 · 95% CI 2.215 to 5.553
SecondaryPharmacokinetics of Dapagliflozin on Day 4 and Day 14

Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)

Time frame:
At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Dapagliflozin on Day 4 and Day 14
ng/mLGroup 2Group 3
Day 4, Pre-dose4.58 ± 134.8819.78 ± 116.54
Day 14, Pre-dose4.54 ± 46.6015.26 ± 41.97
Day 14, 1 h57.46 ± 110.6663.83 ± 150.41
Day 14, 2 h46.47 ± 49.3060.41 ± 140.69
Day 14, 4 h29.71 ± 47.3847.83 ± 100.41
SecondaryNumber of Patients With AEs and SAEs

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.

Time frame:
From Day 1 until Day 18 (Follow-up)
Reported as:
Number · Patients
Number of Patients With AEs and SAEs
PatientsGroup 2Group 3
Any AE62
AEs judged as causally related to dapagliflozin40
AEs leading to death00
SAEs (including outcomes = death)00
SAEs causally related to dapagliflozin00
AEs leading to permanent discontinuation of dapagliflozin00
SAEs leading to permanent discontinuation of dapagliflozin00
Hypoglycaemia AEs00
Hypoglycaemia AEs leading to permanent discontinuation of dapagliflozin00

Adverse events

Collected over Day 1 until Day 18 (FU). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 20/17 (0%)0/17 (0%)6/17 (35.3%)
Group 30/7 (0%)0/7 (0%)2/7 (28.6%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGroup 2Group 3
AnaemiaBlood and lymphatic system disorders0/171/7
MyalgiaMusculoskeletal and connective tissue disorders0/171/7
Head discomfortNervous system disorders2/170/7
DiarrhoeaGastrointestinal disorders1/170/7
NauseaGastrointestinal disorders1/170/7
FatigueGeneral disorders1/170/7
Genital infectionInfections and infestations1/170/7
InfluenzaInfections and infestations1/170/7
FallInjury, poisoning and procedural complications1/170/7
SomnolenceNervous system disorders1/170/7

Baseline characteristics

Safety Set: All patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.

Age, Customized
Age, Customized(Participants)Group 2Group 3Total
<=18 years000
Between 18 and 80 years17724
>=80 years000
Sex: Female, Male
Sex: Female, Male(Participants)Group 2Group 3Total
Female628
Male11516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 2Group 3Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White16723
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Research Site
    Almelo, 7609 PP, Netherlands
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Stockholm, 14186, Sweden
  • Research Site
    Örebro, 70185, Sweden
09

References and documents

Publications

  • Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Hammarstedt A, Karlsson C, Hallow KM, Danser AHJ, Heerspink HJL, van Raalte DH. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet. Kidney Int Rep. 2022 Mar 4;7(5):1084-1092. doi: 10.1016/j.ekir.2022.02.023. eCollection 2022 May. PubMed 35570989 ↗
  • Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, Hammarstedt A, Arya N, van Raalte DH, Heerspink HJL. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 2021 Feb;44(2):440-447. doi: 10.2337/dc20-2604. Epub 2020 Dec 14. PubMed 33318125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Mar 2020, 32 months.

Results were first posted in May 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
May 12, 2017
StartActual
Jul 12, 2017
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Results first posted
May 28, 2021
Last update
May 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03152084
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 12, 2017
Start date
Jul 12, 2017
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Results posted
May 28, 2021
Last update
May 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion